Hypertension · 1993 · 183 citations · 28 references
MedicinePharmacologyPhysiologyCardiovascular PharmacotherapyPathophysiologyPharmacodynamicsBlood Pressure RegulationCardiovascular PharmacologyHypertensive Heart DiseaseAntihypertensive PharmacologyBody Weight RegulationHypertension PathophysiologyInduced HypertensionNitric OxidePlasma Renin ActivityRenin-angiotensin-aldosterone System InhibitionSystolic Blood Pressure
Wistar rats given a nitric oxide synthase inhibitor, NG-nitro-L-arginine-methyl ester (L-NAME), for 4 weeks develop time- and dose-dependent hypertension without cardiac hypertrophy. This initial study of the relation between left ventricular weight and L-NAME-induced hypertension has now been extended by giving 50 mg/kg per day L-NAME to Wistar rats (n = 30) for 8 weeks and comparing results with those from control rats (n = 10) and two-kidney, one clip rats (n = 14). Although L-NAME rats and two-kidney, one clip rats had increased systolic blood pressures during the last 3 weeks of the experiment (202 +/- 24 and 224 +/- 16 mm Hg, respectively), the ratio of left ventricular weight to body weight of L-NAME rats (2.12 +/- 0.32 mg/g) was not statistically different from that of control rats (1.93 +/- 0.13 mg/g), whereas that of two-kidney, one clip rats was increased (2.85 +/- 0.20 mg/g). The plasma renin activity of L-NAME rats was not significantly different from that of control rats. Two L-NAME rat subgroups were defined according to the presence of left ventricular hypertrophy (ratio of left ventricular weight to body weight > 2.19 mg/g, control mean +2 SD) (6 of 25) or its absence (19 of 25). Systolic blood pressure, plasma renin activity, and cardiac angiotensin converting enzyme activity of L-NAME rats with left ventricular hypertrophy were significantly higher than those of the subgroup without.(ABSTRACT TRUNCATED AT 250 WORDS)
28
Endothelium‐derived relaxing and contracting factors
Robert F. Furchgott, Paul M. Vanhoutte · The FASEB Journal · 1989 · 2K citations